BEAM News - Candlesense

U.S. General Services Administration Renews Beam Global Contract Through 2030

Beam Global’s GSA contract renewed through 2030 with Cooperative Purchasing expanding access to federal, state & local agencies.

Contracts

5 days ago

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Beam Therapeutics Inc. (Nasdaq: BEAM) management will be participating in several healthcare investor conferences in September

Investor

6 days ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced tha...

What is the competitive landscape for RMAT‑designated gene therapies, and could Beam face pricing or reimbursement challenges? Are there any partnership or licensing opportunities emerging from this designation that could bring additional funding or expertise? How does Beam’s current cash position and burn rate align with the projected costs of advancing BEAM-101 through late‑stage trials?

Regulatory

17 days ago